Sid Katugampola completed his Ph.D in the Clinical Pharmacology Unit at University of Cambridge. Following that, in 2001 he joined Pfizer R&D and worked across multiple departments spanning 10 years. During his last 6 years at Pfizer, Sid led projects in biomarkers and translational medicine across multiple therapeutic areas and targets with a key focus on demonstrating pharmacodynamic biomarkers in early phase clinical trials. He joined the Centre for Drug Development at Cancer Research UK in 2011 where he has been responsible for the delivery of pharmacodynamic and stratification biomarker strategies for early phase oncology clinical development. He has worked across multiple therapeutic modalities, cancer types, with a strong emphasize on first in class agents.